Vol 5, Supplement 7 (December 29, 2016): Translational Cancer Research


Urachal carcinoma: towards a precision medicine
Alessia Mennitto, Claudio Vernieri, Giuseppe Procopio
Different intellectual outcomes in molecular subgroups of medulloblastoma
Noriyuki Kijima, Yonehiro Kanemura
Indolence versus aggression in non-small cell lung cancer: defining heterogeneity to impact clinical outcomes
Brandon S. Grimes, Kostyantyn Krysan, Linh M. Tran, Stacy J. Park, Denise R. Aberle, Avrum E. Spira, Steven M. Dubinett
Should optimal supportive care alone be the standard of care for brain metastases patients from non-small cell lung cancer, who are not eligible for radiosurgery or surgery?
May N. Tsao
BRAF inhibitors in advanced BRAF-positive non-small cell lung cancer
Tiziana Vavalà
Cell intrinsic PD-1 checkpoint blockade releases the brake on human chimeric antigen receptor (CAR) T cells for solid tumors
Joseph A. Fraietta, J. Joseph Melenhorst, Bruce L. Levine
Personalized peptide vaccine in prostate cancer: capitalizing on existing immunity
Ravi A. Madan, James L. Gulley
Simplicity is complexity resolved”: the case of postoperative radiation therapy after breast conservation
Pierfrancesco Franco, Gary M. Freedman, Umberto Ricardi, Philip Poortmans
Emerging multikinase inhibitors for the treatment of differentiated thyroid cancer: whom to treat?
Jolanta Krajewska, Dagmara Rusinek, Barbara Jarzab
Routine prophylactic drainage in rectal surgery—closing the chapter?
Martine A. Frouws, Cornelis J. H. van de Velde
Tumor treating fields—effective, but at what cost?
Isabella Zhang, Jonathan P. S. Knisely
A cytological link between radioresistance and autophagy
Kuan-Chih Chow
Hypoxia-induced DNA hypermethylation: another reason to normalize tumor vessels
Mei Rosa Ng, Rakesh K. Jain
Relapsed small cell lung cancer: is more better?
Vinicius Ernani, Apar Kishor Ganti
JMJD3 histone demethylase—a potential therapeutic target for metastatic hepatocellular carcinoma?
Sai-Kam Li, Yick Pang Ching
Is combined chemotherapy with cisplatin, etoposide and irinotecan the new standard treatment for patients with sensitive relapsed small cell lung cancer?
Alessandro Morabito
Hypofractionated radiotherapy for breast cancer: how to evaluate chronic toxicity and cosmesis?
Javier Sanz, Nuria Rodríguez, Manuel Algara
Sentinel node biopsy in combination with extended pelvic lymph node dissection for men with prostate cancer at risk of nodal involvement
Mauro Gacci, Pietro Spatafora, Sergio Serni
Omission of adjuvant radiotherapy in early-stage breast cancer: have we identified a subgroup?
Angela Lin
Trunk or branch? Identifying and targeting intratumoral heterogeneity in hepatocellular carcinoma using genomics and patient derived primary cancer cells
Kelsey E. Wuensch, Aik Choon Tan
Micropapillary urothelial carcinoma: is molecular hair-splitting on target?
Nuzhat Husain, Azfar Neyaz
Distinct benefit from crizotinib in lung cancer patients carrying distinct ALK translocations: is fluorescent hybridization in situ testing still sufficient to guide clinical decisions?
Natalia V. Mitiushkina, Evgeny N. Imyanitov
PD-L1 is a diverse molecule regulating both tumor-intrinsic signaling and adaptive immunosuppression
Kim A. Brogden, Shireen Vali, Taher Abbasi
Transgenic mouse models of Idh-mutated neural stem cells: an appropriate model for low grade glioma?
William Leenders
Pelvic drain after colorectal anastomosis: useful or useless
Varut Lohsiriwat
A transcriptional-microRNA network for β-catenin-driven stemness in hepatocellular carcinoma
William K.K. Wu, Matthew T.V. Chan, Alfred S.L. Cheng
Adding chemotherapy to TKI: can we improve first-line treatment for EGFR-mutated NSCLC patients?
Francesco Passiglia, Antonio Russo


Predictive biomarkers for prostate brachytherapy—not there yet
Jaimee C. Eckers, Randall J. Kimple
PGC1α curtails prostate cancer metastasis via metabolic rewiring
Erica J. McDonald, Vanessa S. Arciero, Urban Emmenegger
How far have we achieved by systemic therapy for recurrent/metastatic nasopharyngeal carcinoma?
Victor Lee
A new approach to high risk pediatric acute lymphoblastic leukemia?
Diane Hanna, Mary Ann Anderson
When tumors are (co-)opting to resist anti-angiogenic treatment
Lasse D. Jensen
Versikine, a proteolysis product of Versican: novel therapeutics for multiple myeloma
Nidhi Gupta, Raman Kumar, Alpana Sharma
The role of long noncoding RNA FOXF1-AS1 as a tumor suppressor in non-small cell lung cancer
Hao Zheng, Aswini R. Krishnan, Angela E. Zou, Weg M. Ongkeko
Checkpoints inhibitors in first line therapy of metastatic non-small cell lung cancer patients
Luis E. Raez, Christian Rolfo, Mauricio Mahave, Christian Caglevic
Trimming the fat in non-small cell lung cancer: a new small molecule inhibitor of acetyl-CoA carboxylase to target fatty acid synthesis
Amanda L. Davis, Steven J. Kridel
Repurposing multiple sclerosis drug dimethyl fumarate, a promising fast track candidate for systemic cutaneous T cell lymphoma treatment
Martin Herold, Luisa Klotz
The Wnt/β-catenin pathway is activated by miR-1246 in liver cancer stem cells
Melanie A. Eshelman, Gregory S. Yochum
Targeting B-Raf kinase for thyroid cancer treatment: promise and challenge
Xiulong Xu, Richard A. Prinz
Toward the clarification of the role of whole-brain radiation therapy for brain metastases from non-small cell lung cancer: a comment about the QUARTZ trial
Hirotake Saito, Toshimichi Nakano, Miki Shioi, Hidefumi Aoyama
Utility of gene expression signature in treatment decision of breast cancer
Seema Thakur, Ankan Mukherjee Das, Bhudev C. Das
Major thoracic surgery in patients under antiplatelet therapy
Francesco Cassiano, Cecilia Menna, Claudio Andreetti, Mohsen Ibrahim
Empiric H. pylori therapy—10-day concomitant, bismuth quadruple or 14-day triple therapy: none is best
Yoshio Yamaoka, David Y. Graham
miRNA transported by exosomes: a key machinery in tumor microenvironment mediated chemoresistance
Teresa Gagliano, Thomas Simon, Georgios Giamas
Rac1 and EMT: a dangerous liaison?
Javier Vaquero, Laura Fouassier
Secreted reporter proteins, a valuable complementary tool for non-invasive preclinical monitoring of brain tumour growth
Ludwig J. Dubois, Frank Verhaegen, Marc A. Vooijs
[18F]-choline PET/CT as an imaging biomarker for primary liver cancers
Zhenghong Lee
Direct acting antivirals for hepatitis c and hepatocellular carcinoma recurrence: an unsolved mystery
Virginia A. Dines, Michael D. Leise


Perspective on the regulatory role of UGT2B28 as a conjugating enzyme in the progression of prostate cancer
Therina du Toit, Amanda C. Swart
HIF-pathway proteins: central regulators of tumor immunology
Sundary Sormendi, Ben Wielockx
Small molecule inhibition of speckle-type POZ protein-substrate interactions for the treatment of renal cell carcinoma
Byung Joon Hwang, Yun Kee
Tumor intrinsic resistance to anti-programmed death 1
Jacqueline Liu, Ting Fang, Adil I. Daud
Transoral endoscopic thyroidectomy: current state of the art—a systematic literature review and results of a bi-center study
Thomas Wilhelm, Guoyang Wu, Afshin Teymoortash, Christian Güldner, Thomas Günzel, Stefan Hoch
DNA hypermethylation of tumor suppressor genes as an early lung cancer biomarker
Tomasz Powrózek, Teresa Małecka-Massalska
Evolving concepts of micropapillary variant urothelial carcinoma
M. Francesca Monn, Liang Cheng
Programmed death ligand 1 expression and human papillomavirus status: penile cancer prognostic factors and new therapeutic opportunities
Kelly L. Stratton, Mohammad Ramadan, Ahmed Eldefrawy, Daniel J. Culkin


This supplement was published without any sponsorship or funding.